Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial Meeting Abstract
| Authors: | Burotto, M.; Powles, T.; Escudier, B.; Apolo, A. B.; Bourlon, M. T.; Shah, A. Y.; Suárez, C.; Porta, C.; Barrios, C. H.; Richardet, M.; Gurney, H.; Kessler, E. R.; Tomita, Y.; Bedke, J.; George, S.; Scheffold, C.; Wang, P.; Fedorov, V.; Motzer, R. J.; Choueiri, T. K. |
| Abstract Title: | Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial |
| Meeting Title: | 2023 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2023 Feb 16-18 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-02-20 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.6_suppl.603 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting abstract: 603 --Accession Number: 162006836 -- Entry Date: In Process -- Revision Date: 20230223 -- Publication Type: Article -- Supplement Title: 2/21/2023 Supplement -- Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA -- NLM UID: 8309333. -- Source: Cinahl |
